NDDS Important Questions Unit-wise (Novel Drug Delivery System, BP704T)
By Vignesh, Pharma Graduate · Member of LBP · Updated November 2026
Novel Drug Delivery System (NDDS) is full of systems that sound alike: matrix and reservoir, osmotic pumps and implants, liposomes and niosomes. Students lose marks by mixing them up. The way out is to prepare the repeated questions with a fixed answer structure.
Here are the NDDS important questions unit-wise for B.Pharm Semester 7 (BP704T, PCI syllabus). Start with the ★ questions, then read the two sample answers and try the MCQs at the end.
Want every answer written out? The NDDS Exam Pack has model answers for all the ★ questions. Just ₹49. See the pack →
Novel Drug Delivery System exam pattern (BP704T)
Section
Questions
Marks
I. Objective (MCQs / fill in the blanks / one-word)
10 × 2 (or 20 × 1)
20
II. Long answers
Answer 2 of 3 × 10
20
III. Short answers
Answer 7 of 9 × 5
35
Total
3 hours
75
For every delivery system, write: definition → advantages and limitations → types or approaches → formulation components → evaluation, with a labelled diagram.
Novel Drug Delivery System important questions, unit-wise
★ marks the questions asked most often in university papers. Prepare these first.
Unit I: Controlled drug delivery systems and polymers
Long (10 marks)
★ Define controlled drug delivery. Discuss its advantages, disadvantages, the selection of drug candidates, and the physicochemical and biological factors in design.
★ Explain the approaches to the design of controlled release systems (dissolution, diffusion, dissolution–diffusion, osmotic, ion exchange).
Define polymers. Classify them and discuss their properties and applications in controlled release.
Short (5 marks)
★ Sustained vs controlled release · Biodegradable polymers (PLGA) · Matrix and reservoir systems · Ion exchange resins
Unit II: Microencapsulation, mucoadhesion, implants
Long
★ Define microencapsulation. Discuss the methods of preparation of microcapsules and microspheres (coacervation, spray drying, solvent evaporation, air suspension, pan coating) and their evaluation.
★ Define mucoadhesion. Explain the theories, factors affecting mucoadhesion, and buccal drug delivery.
Short
★ Microspheres vs microcapsules · Mucoadhesive polymers · Implantable drug delivery systems · Osmotic pumps (OROS, Alzet)
Unit III: Transdermal, gastroretentive, nasopulmonary
Long
★ Describe the transdermal drug delivery system: skin structure, permeation pathways, factors, components (polymer matrix, drug, enhancers, adhesive, backing, liner), types of TDDS and evaluation.
★ Explain the approaches to gastroretentive drug delivery (floating, high-density, swelling, mucoadhesive, raft-forming).
Short
★ Permeation enhancers · Iontophoresis · Floating drug delivery systems · Intranasal drug delivery · Pulmonary delivery: MDI, DPI, nebulisers
Unit IV: Targeted drug delivery
Long
★ Explain the concept of targeted drug delivery (passive, active, physical targeting; first, second and third order). Describe liposomes: classification, preparation, evaluation and applications.
Here are 2 answers written the way examiners like them. The pack has model answers for every ★ question.
Niosomes (5 marks)
Definition:niosomes are non-ionic surfactant vesicles: bilayer vesicles formed from non-ionic surfactants (± cholesterol) in an aqueous medium. They are structurally similar to liposomes but use non-ionic surfactants instead of phospholipids. (First reported for cosmetics by L’Oréal in the 1970s–80s.)
Cholesterol: stabilises the bilayer (increases rigidity, reduces leakage).
Charge inducers: dicetyl phosphate (negative) or stearylamine (positive).
Hydration medium (buffer).
Methods of preparation: similar to liposomes: thin film hydration (hand shaking), ether injection, reverse-phase evaporation, sonication, membrane extrusion, microfluidisation, the bubble method (no organic solvents), “proniosome” technology (a dry, free-flowing powder of surfactant coated on a carrier (sorbitol, maltodextrin), which forms niosomes on hydration: improves stability).
Niosomes vs liposomes:
Liposomes
Niosomes
Made of phospholipids
Made of non-ionic surfactants
Chemically unstable (phospholipids oxidise and hydrolyse)
More chemically stable
Expensive (purified phospholipids)
Cheaper
Need special storage (cold, inert atmosphere)
No special storage or handling needed
Natural lipids: variable purity
Surfactants of uniform quality
Both carry hydrophilic and lipophilic drugs; both are biocompatible
Some surfactants may cause irritation or haemolysis
Advantages:osmotically active and stable; improve oral bioavailability of poorly absorbed drugs; increase skin penetration (topical delivery); targeting (RES uptake, tumours); sustained release; and low cost.
Applications:
Anticancer drugs (methotrexate, doxorubicin: altered distribution, less toxicity).
Leishmaniasis (sodium stibogluconate niosomes: higher liver and spleen levels).
Evaluation: as for liposomes (size, zeta potential, entrapment efficiency, in vitro release, morphology, stability).
Targeted drug delivery: concepts (5 marks)
Definition:targeted (site-specific) drug delivery is the selective delivery of a drug to its site of action (target organ, tissue or cell) in such a way that the drug reaches its target while minimising exposure to non-target sites. The concept of the “magic bullet” was put forward by Paul Ehrlich (1906).
Advantages:
Higher drug concentration at the target and better efficacy.
Lower dose required.
Fewer side effects and lower toxicity (especially for anticancer drugs).
Protection of the drug from degradation; prolonged circulation.
Possible delivery of genes, proteins and peptides.
Reduced fluctuations in drug levels.
Disadvantages:rapid clearance of carriers by the RES (reticuloendothelial system: liver, spleen; macrophages); immune reactions; difficulty crossing biological barriers; complex manufacture, high cost, stability problems, limited drug loading, and the need for skilled handling.
Levels of targeting:
First-order targeting: to a specific organ or tissue (e.g. compartment targeting: intraperitoneal, intra-articular, intrathecal, lymphatic, the lungs).
Second-order targeting: to specific cells within a tissue (e.g. tumour cells, Kupffer cells of the liver).
Third-order targeting: to specific intracellular sites (e.g. lysosomes (endocytosis), the nucleus (gene delivery), mitochondria).
Approaches to targeting:
Passive targeting: uses the natural distribution of carriers in the body according to their physicochemical properties (size, surface charge, hydrophobicity).
RES uptake: carriers (> 100 nm) are taken up by macrophages of the liver and spleen (useful for liver diseases, leishmaniasis, fungal infections: e.g. liposomal amphotericin B (AmBisome)).
Enhanced permeability and retention (EPR) effect (Matsumura and Maeda, 1986): tumour blood vessels are leaky (with gaps of 100–800 nm) and tumours have poor lymphatic drainage, so nanocarriers (10–200 nm) accumulate and are retained in tumours (e.g. Doxil: PEGylated liposomal doxorubicin).
Size-based filtering: microparticles (7–12 µm) are trapped in the lung capillaries after IV injection.
Inverse targeting: blocking the RES (e.g. with blank carriers or dextran sulphate) to avoid uptake of carriers by the RES, so they reach other sites.
Active targeting: carriers are modified with ligands that bind specifically to receptors or antigens on target cells:
Antibodies and antibody fragments (immunoliposomes; antibody–drug conjugates, e.g. trastuzumab emtansine (Kadcyla)).
Folic acid (folate receptors are over-expressed on many cancer cells), transferrin (transferrin receptors: brain, tumours), peptides (RGD: integrins), aptamers, galactose (asialoglycoprotein receptors on hepatocytes), mannose (macrophages).
Stealth (long-circulating) carriers: PEGylation (coating with polyethylene glycol) reduces opsonisation and RES uptake, prolonging circulation.
Physical targeting: the carrier responds to an external stimulus at the target site:
Magnetic (magnetic microspheres guided by an external magnet).
Temperature (thermosensitive liposomes with local hyperthermia).
pH (pH-sensitive carriers release the drug in the acidic tumour or endosomal environment).
Ultrasound, light (photodynamic therapy), and electric fields.
Dual and double targeting: a combination of approaches (e.g. carrier + prodrug, temporal and spatial targeting).
Unit I (controlled release concepts and polymers), Unit III (transdermal and gastroretentive systems) and Unit IV (targeted delivery, liposomes) give most of the long answers.
What is the difference between liposomes and niosomes?
Liposomes are vesicles made of phospholipids; niosomes are made of non-ionic surfactants with cholesterol. Niosomes are cheaper and more chemically stable.
How do I remember the evaluation tests in NDDS?
Group them: physical (size, shape, thickness), drug content and entrapment, in-vitro release, and stability. The same groups work for most systems.
Is NDDS the same as BP704T?
Yes. In the PCI B.Pharm syllabus, Novel Drug Delivery System is the Semester 7 theory paper BP704T.
NDDS EXAM PACK · B.PHARM SEM 7
All the unit-wise important questions above with 16 model answers in exam format, 46 MCQs with explanations, in one PDF. Instant download. ₹49₹99